

## Landiolol

## Chemical Properties


CAS No. : 133242-30-5

Formula: C<sub>25</sub>H<sub>39</sub>N<sub>3</sub>O<sub>8</sub>

Molecular Weight: 509.59

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Landiolol is used as a highly cardioselective ultra short-acting beta-blocker.
Targets(IC50)	Others,Calcium Channel,Adrenergic Receptor,Potassium Channel,ROS

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9624 mL	9.8118 mL	19.6236 mL
5 mM	0.3925 mL	1.9624 mL	3.9247 mL
10 mM	0.1962 mL	0.9812 mL	1.9624 mL
50 mM	0.0392 mL	0.1962 mL	0.3925 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting  $\beta$ 1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. *World J Crit Care Med.* 2015 Aug 4;4(3):251-7. doi: 10.5492/wjccm.v4.i3.251. eCollection 2015 Aug 4. PubMed PMID: 26261777; PubMed Central PMCID: PMC4524822.

Xiao J, He P, Zou Q, Zhao Y, Xue Z, Deng X, Li S, Guo Q, Tao G, Yang T, Lang Z, He J, Wang X. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Anesth.* 2015 Mar;27(2):120-8. doi: 10.1016/j.jclinane.2014.07.003. Epub 2014 Nov 28. PubMed PMID: 25434501.

Kunisawa T, Yamagishi A, Suno M, Nakade S, Higashi R, Kurosawa A, Sugawara A, Matsubara K, Iwasaki H. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients. *J Anesth.* 2015 Apr;29(2):198-205. doi: 10.1007/s00540-014-1908-5. Epub 2014 Sep 4. PubMed PMID: 25186494.

Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. *Adv Ther.* 2014 Apr;31(4):426-39. doi: 10.1007/s12325-014-0111-2. Epub 2014 Mar 19. Erratum in: *Adv Ther.* 2014 May;31(5):577-8. PubMed PMID: 24643403; PubMed Central PMCID: PMC4003342.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481